Kinase platform

Our Oncology unit has developed a methodological platform to discover small molecule kinase inhibitors, which we refer to as the ‘Kinase Platform’. A panel of over 90 cloned and expressed kinases is set up for regularly scheduled selectivity screens. Hundreds of crystal structures are available for the rational planning of hit expansions by parallel synthesis. Periodically, High Throughput Screening campaigns are run in order to jump start new kinase inhibition projects by testing a.o. well over 60,000 compounds from our ‘Kinase Targeted Libraries’ prepared over the years.

To give you a better browsing experience, NMS Group and Group Companies use own and third part cookies.
Browsing this web site, you allow to use them, according to our  
Cookie Policy.